Marina Mata

Marina Mata

Auto-generated profile, based on publicly available information

Marina Mata

Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Experimental Neurology
Verified
Journal Article
Closed access
ZZZhigang Zhou
Zhigang Zhou
XPXiangmin Peng
Xiangmin Peng
RIRyan Insolera
Ryan Insolera
DFDavid J. Fink
David J. Fink
MMMarina Mata
Marina Mata

10 August 2009 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
ZZZhigang Zhou
Zhigang Zhou
XPXiangmin Peng
Xiangmin Peng
RIRyan Insolera
Ryan Insolera
DFDavid J. Fink
David J. Fink
MMMarina Mata
Marina Mata
Interleukin (IL)‐10, a prototypical anti‐inflammatory cytokine, has been shown to provide beneficial effects in neuronal injuryin vivobut the full range of actions has not been established. In order to understand the neuronal mechanisms underlying IL‐10‐mediated neuroprotection, we examined the effect of IL‐10 on primary neurons in culture. We found that IL‐10 exerted a direct trophic influence on spinal cord neurons, and that activation of the neuronal IL‐10 receptor provided trophic support and survival cues to overcome the neurotoxic effects of glutamatein vitro. IL‐10 treatment resulted in activation of janus‐associated kinases/signal transducers and transcription factors and phosphatidylinositol 3‐kinase‐AKT pathways in neurons to enhance expression of Bcl‐2 and Bcl‐xL; under stress conditions IL‐10 blocks cytochromecrelease and caspase cleavage. IL‐10 activation of the canonical nuclear factor κB pathway enhanced translocation of p50 and p65 and enhanced their binding to κB DNA sequences, with p50 playing a more prominent role in neuronal survival. These data indicate that in addition to known anti‐inflammatory effects through astroglia in other inflammatory cells, IL‐10 has direct neuronal effects with important implications for development and neuroprotection.

1 January 2006 in Molecular Pain
Verified
Journal Article
Open access
SHShuanglin Hao
Shuanglin Hao
MMMarina Mata
Marina Mata
JGJoseph Charles Glorioso
Joseph Charles Glorioso
DFDavid J Fink
David J Fink
Background: To examine the role of inflammatory mediators in neuropathic pain, we used a replication-defective genomic herpes simplex virus (HSV)-based vector containing the coding sequence for the anti-inflammatory peptide interleukin (IL)-4 under the transcriptional control of the HSV ICP4 immediate early promoter, vector S4IL4, to express IL-4 in dorsal root ganglion (DRG) neurons in vivo. Results: Subcutaneous inoculation of S4IL4 in the foot transduced lumbar DRG to produce IL-4. Transgene-mediated expression of IL-4 did not alter thermal latency or tactile threshold in normal animals, but inoculation of S4IL4 1 week after spinal nerve ligation (SNL) reduced mechanical allodynia and reversed thermal hyperalgesia resulting from SNL. Inoculation of S4IL4 1 week before SNL delayed the development of thermal hyperalgesia and tactile allodynia, but did not prevent the ultimate development of these manifestations of neuropathic pain. S4IL4 inoculation suppressed non-noxious-induced expression of c-Fos immunoreactivity in dorsal horn of spinal cord and reversed the upregulation of spinal IL-1β, PGE2, and phosphorylated-p38 MAP kinase, characteristic of neuropathic pain. Conclusion: HSV-mediated expression of IL-4 effectively reduces the behavioral manifestations of neuropathic pain, and reverses some of the biochemical and histologic correlates of neuropathic pain at the spinal level.

1 January 2011 in Molecular Pain
Verified
Journal Article
Open access
PDF file
WZWenwen Zheng
Wenwen Zheng
HOHandong Ouyang
Handong Ouyang
XZXuexing Zheng
Xuexing Zheng
SLShue Liu
Shue Liu
MMMarina Mata
Marina Mata
SHShuanglin Hao
Shuanglin Hao
Background: HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral neuropathy, affecting about 30% of people with acquired immune deficiency syndrome (AIDS). The symptoms of HIV-SN are dominated by neuropathic pain. Glia activation in the spinal cord has become an attractive target for attenuating chronic pain. This study will investigate the role of spinal TNFα released from glia in HIV-related neuropathic pain.Results: Peripheral gp120 application into the rat sciatic nerve induced mechanical allodynia for more than 7 weeks, and upregulated the expression of spinal TNFα in the mRNA and the protein levels at 2 weeks after gp120 application. Spinal TNFα was colocalized with GFAP (a marker of astrocytes) and Iba1 (a marker of microglia) in immunostaining, suggesting that glia produce TNFα in the spinal cord in this model. Peripheral gp120 application also increased TNFα in the L4/5 DRG. Furthermore, intrathecal administration of TNFα siRNA or soluble TNF receptor reduced gp120 application-induced mechanical allodynia.Conclusions: Our results indicate that TNFα in the spinal cord and the DRG are involved in neuropathic pain, following the peripheral HIV gp120 application, and that blockade of the glial product TNFα reverses neuropathic pain induced by HIV gp120 application.

22 November 2007 in Gene Therapy
Verified
Journal Article
Open access
PDF file
ZZZ Zhou
Z Zhou
XPX Peng
X Peng
SHS Hao
S Hao
DFD J Fink
D J Fink
MMM Mata
M Mata
To dissect the molecular basis of the neuroimmune response associated with the genesis of inflammatory (nociceptive) pain, we constructed a herpes simplex virus-based gene transfer vector to express the antiinflammatory cytokine interleukin-10 (IL-10), and used it to examine the effect of IL-10 expression in activated microglial cells in vitro, and in inflammatory pain in vivo. IL-10 reduced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) and decreased the expression of full-length membrane spanning tumor necrosis factor-α (mTNFα) following lipopolysaccharide stimulation of microglia in vitro. IL-10 also reduced intracellular cleavage of mTNFα and release of the soluble cleavage product sTNFα. Similar effects on TNFα expression were observed when the cells were pretreated with a p38 MAPK inhibitor. In animals, injection of a dilute solution of formalin in the skin resulted in an increase in mTNFα in spinal dorsal horn, without detectable sTNFα. Local release of IL-10 achieved by gene transfer reduced the number of spontaneous flinches in the early and delayed phases of the formalin test of inflammatory pain. The effect of IL-10 on nocisponsive behavior correlated with a block in phosphorylation of p38 and reduced expression of 26 kDa mTNFα in spinal microglia. The results emphasize the key role played by membrane TNFα in the spinal neuroimmune response in pain caused by peripheral inflammation.

1 January 2012 in Molecular Pain
Verified
Journal Article
Open access
MCMunmun Chattopadhyay
Munmun Chattopadhyay
ZZZhigang Zhou
Zhigang Zhou
SHShuanglin Hao
Shuanglin Hao
MMMarina Mata
Marina Mata
DFDavid J Fink
David J Fink
Background: Painful neuropathy is a common complication of diabetes. Previous studies have identified significant increases in the amount of voltage gated sodium channel isoforms NaV1.7 and NaV1.3 protein in the dorsal root ganglia (DRG) of rats with streptozotocin (STZ)-induced diabetes. We found that gene transfer-mediated release of the inhibitory neurotransmitters enkephalin or gamma amino butyric acid (GABA) from DRG neurons in diabetic animals reduced pain-related behaviors coincident with a reduction in NaV1.7 protein levels in DRG in vivo. To further evaluate the role of NaVα subunit levels in DRG in the pathogenesis of pain in diabetic neuropathy, we constructed a nonreplicating herpes simplex virus (HSV)-based vector expressing a microRNA (miRNA) against NaVα subunits. Results: Subcutaneous inoculation of the miRNA-expressing HSV vector into the feet of diabetic rats to transduce DRG resulted in a reduction in NaVα subunit levels in DRG neurons, coincident with a reduction in cold allodynia, thermal hyperalgesia and mechanical hyperalgesia. Conclusions: These data support the role of increased NaVα protein in DRG in the pathogenesis of pain in diabetic neuropathy, and provide a proof-of-principle demonstration for the development of a novel therapy that could be used to treat intractable pain in patients with diabetic neuropathy.